Zobrazeno 1 - 10
of 1 375
pro vyhledávání: ''
Autor:
Brett H. Herzog, Saiama N. Waqar, Siddhartha Devarakonda, Jeffrey P. Ward, Feng Gao, Ramaswamy Govindan, Daniel Morgensztern
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 173
The treatment options for patients with stage IV non-small cell lung cancer (NSCLC) who develop tumor progression after platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) are limited. The combination of ICI with inhibitors of vascula
Autor:
Nikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, Matthias Raspe, Elisabeth Olive, Alexander Schmittel, Bernd Schmidt, David Wasilewski, Julia Onken, Heike Lüders, Martin Witzenrath, Carolin Senger, Dirk Böhmer, Sonja Loges, Frank Griesinger, Dominik P. Modest, Christian Grohé
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
Local ablative therapy (LAT) improves survival in oligometastatic lung cancer (OMD), but there is limited information on recurrence patterns, re-treatments and in particular the role of brain metastases during the course of disease. We therefore cond
Autor:
Chang Liu, Cuicui Liu, Jiatao Liao, Jiani C. Yin, Xianghua Wu, Xinmin Zhao, Si Sun, Huijie Wang, Zhihuang Hu, Yao Zhang, Hui Yu, Yang Shao, Jialei Wang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 171
Crizotinib remains one of the most commonly used targeted therapies for ALK fusion-positive patients. However, the mutational profiles and mechanisms of resistance to first-line crizotinib treatment remain to be thoroughly examined.We retrospectively
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 171
Objectives: Mean age at diagnosis of lung cancer is increasing with increasing age in Western populations. The present study was designed to evaluate the effect of adherence to first-line treatment guidelines on overall survival (OS) in elderly patie
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Asian patients with metastatic non-small cell lung cancer (NSCLC) have a higher prevalence of epidermal growth factor receptor (EGFR) mutations compared to Caucasians, 30-50% and 15%, respectively. Osimertinib is a tyrosine kinase inhibitor approved
Autor:
Ariadna Juarez-Garcia, Ruchika Sharma, Matthias Hunger, Sheena Kayaniyil, John R. Penrod, Christos Chouaïd
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Clinical trials have shown immunotherapy (IO) to be more effective than chemotherapy in pre-treated, advanced non-small cell lung cancer (NSCLC). However, there is a lack of understanding of its effectiveness in clinical practice, and among patient g
Autor:
Keith Sigel, Chung Yin Kong, Amanda Leiter, Minal Kale, Grace Mhango, Brian Huang, Michael K. Gould, Juan Wisnivesky
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
Non-small cell lung cancer (NSCLC) patients frequently have major comorbidities but there is scarce data regarding the impact of these conditions on management strategies. We used simulation modeling to compare different treatments for stage I NSCLC
Autor:
Mikey B. Lebrett, Emma J. Crosbie, Janelle Yorke, Kath Hewitt, Ailsa Rowlands, Ellena Badrick, D. Gareth Evans, Haval Balata, Richard Booton, Philip A.J. Crosbie
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 168
In England, a risk-based approach is used to determine eligibility for lung cancer screening. Ensuring effective communication and counselling of risk is therefore increasingly important. In this study, we explore the perception of lung cancer risk i
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
Lung cancer (LC) remains a burden for patients and healthcare systems, with most cases only diagnosed once disease is late stage. Screening for LC with low-dose computed tomography (LDCT) has shown a stage shift and led to a lung cancer-specific mort
Autor:
Monica Tang, Chee K. Lee, Craig R. Lewis, Michael Boyer, Bernadette Brown, Andrea Schaffer, Sallie-Anne Pearson, Robert J. Simes
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Based on data from randomized controlled trials (RCTs), immune checkpoint inhibitors (ICI) are standard-of-care in advanced non-small cell lung cancer (aNSCLC). However, trial eligibility criteria are restrictive, and participants and outcomes may no